Second-Eye gene therapy trial offers hope for rare vision loss
NCT ID NCT06646289
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This study tests a gene therapy given to the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. About 24 adults and children who already received treatment in one eye will get the therapy in their other eye. Researchers will check for side effects and measure changes in eyesight, including how well participants see in low light.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, 02114, United States
-
Moorfields Eye Hospital
London, EC1V 2PD, United Kingdom
-
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, 48105, United States
Conditions
Explore the condition pages connected to this study.